Evidence map›Paper›PMID 28253204›Full record

ArticleAcademic medicine : journal of the Association of American Medical Colleges2017

Expanding Local Cancer Clinical Trial Options: Analysis of the Economic Impact of the Midwest Cancer Alliance in Kansas.

J Atlee Gafford, Tami Gurley-Calvez, Hope Krebill, Sue Min Lai, Christiadi, Gary C Doolittle

Abstract read
In one paragraph

Article in Academic medicine : journal of the Association of American Medical Colleges, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

J Atlee GaffordJ.A. Gafford is a PhD student, Department of Health Policy and Management, University of Kansas School of Medicine, Kansas City, Kansas. T. Gurley-Calvez is associate professor, Department of Health Policy and Management, University of Kansas School of Medicine, Kansas City, Kansas. H. Krebill is executive director, Midwest Cancer Alliance, Kansas City, Kansas. S.M. Lai is professor, Preventive Medicine and Public Health, and director, Kansas Cancer Registry, University of Kansas School of Medicine, Kansas City, Kansas. Christiadi is research associate/demographer, Bureau of Business and Economic Research, West Virginia University, Morgantown, West Virginia. G.C. Doolittle is Capital Federal Masonic Professor, Medical Oncology, and medical director, Center for Telemedicine and Telehealth, University of Kansas School of Medicine, as well as medical director, Midwest Cancer Alliance, Kansas City, Kansas.
Tami Gurley-Calvez
Hope Krebill
Sue Min Lai
Christiadi
Gary C Doolittle

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients benefit from receiving cancer treatment closer to home when possible and at high-volume regional centers when specialized care is required. The purpose of this analysis was to estimate the economic impact of retaining more patients in-state for cancer clinical trials and care, which might offset some of the costs of establishing broader cancer trial and treatment networks.

methodKansas Cancer Registry data were used to estimate the number of patients retained in-state for cancer care following the expansion of local cancer clinical trial options through the Midwest Cancer Alliance based at the University of Kansas Medical Center. The 2014 economic impact of this enhanced local clinical trial network was estimated in four parts: Medical spending was estimated on the basis of National Cancer Institute cost-of-care estimates. Household travel cost savings were estimated as the difference between in-state and out-of-state travel costs. Trial-related grant income was calculated from administrative records. Indirect and induced economic benefits to the state were estimated using an economic impact model.

resultsThe authors estimated that the enhanced local cancer clinical trial network resulted in approximately $6.9 million in additional economic activity in the state in 2014, or $362,000 per patient retained in-state. This estimate includes $3.6 million in direct spending and $3.3 million in indirect economic activity. The enhanced trial network also resulted in 45 additional jobs.

conclusionsRetaining patients in-state for cancer care and clinical trial participation allows patients to remain closer to home for care and enhances the state economy.

Indexed as

Models, EconomicSocial EnvironmentCancer Care FacilitiesClinical Trials as TopicCost-Benefit AnalysisFemaleHealth Services ResearchHumansKansasMaleRegistriesTravel

Identifiers

PMID28253204
PMCPMC5574436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.